Background: Asthma is one of the most common chronic respiratory diseases in the world, standing for the most frequent cause for hospitalization and emergency cases. Respiratory viruses are the most triggering cause. Aim: To assess the role of viral infections, especially COVID-19, in the pathogenesis of asthma initiation and exacerbations. Method: Electronic search was done for the manuscripts focusing on asthma as a risk factor for complications after COVID-19 infection. The outcomes were titles, materials, methods and classified studies related or not related to the review study. Three hundred publications were identified and only ten studies were selected for analysis. Seven studies were review, one retrospective, one longitudinal cohort study and one letter to the editor. Results: The included literature sources have highlighted different effect of asthma on COVID-19 progression. Asthma can be triggered by this virus and asthmatic patients with COVID-19 should not stop their treatment. Others suggest that asthma does not appear to be a significant risk factor for developing severe COVID-19 requiring hospitalization or intubation. Conclusions: Asthma is considered as comorbidity factor leading to complications and mortality in subjects infected with COVID-19.
References
1.
Jackson DJ, Makrinioti H, Rana BMJ, Shamji BWH, Trujillo-Torralbo MB, Footitt J, et al. IL-33–Dependent Type 2 Inflammation during Rhinovirus-induced Asthma Exacerbations In Vivo. American Journal of Respiratory and Critical Care Medicine. 2014;190(12):1373–82.
2.
Abrams EM, ‘t Jong GW, Yang CL. Asthma and COVID-19. Canadian Medical Association Journal. 2020;192(20):E551–E551.
3.
Wang J, Pawankar R, Tsai H, Wu LS, Kuo W. COVID‐19 and asthma, the good or the bad? Allergy. 2021;76(2):565–7.
4.
Peters MC, Fahy JV. Erratum: COVID-19–related Genes in Sputum Cells in Asthma: Relationship to Demographic Features and Corticosteroids. American Journal of Respiratory and Critical Care Medicine. 2020;202(12):1744–6.
5.
Liu S, Zhi Y, Ying S. COVID-19 and Asthma: Reflection During the Pandemic. Clinical Reviews in Allergy & Immunology. 2020;59(1):78–88.
6.
Hartmann-Boyce J, Gunnell J, Drake J, Otunla A, Suklan J, Schofield E, et al. Asthma and COVID-19: review of evidence on risks and management considerations. BMJ Evidence-Based Medicine. 2021;26(4):195–195.
7.
Broadhurst R, Peterson R, Wisnivesky JP, Federman A, Zimmer SM, Sharma S, et al. Asthma in COVID-19 Hospitalizations: An Overestimated Risk Factor? Annals of the American Thoracic Society. 2020;17(12):1645–8.
8.
Bochkov YA, Gern JE. Rhinoviruses and Their Receptors: Implications for Allergic Disease. Current Allergy and Asthma Reports. 2016;16(4).
9.
Nakagome K, Bochkov YA, Ashraf S, Brockman-Schneider RA, Evans MD, Pasic TR, et al. Effects of rhinovirus species on viral replication and cytokine production. Journal of Allergy and Clinical Immunology. 2014;134(2):332-341.e10.
10.
Morais-Almeida M, Pité H, Aguiar R, Ansotegui I, Bousquet J. Asthma and the Coronavirus Disease 2019 Pandemic: A Literature Review. International Archives of Allergy and Immunology. 2020;181(9):680–8.
11.
Beale J, Jayaraman A, Jackson DJ, Macintyre JDR, Edwards MR, Walton RP, et al. Rhinovirus-induced IL-25 in asthma exacerbation drives type 2 immunity and allergic pulmonary inflammation. Science Translational Medicine. 2014;6(256).
12.
Saglani S, Lui S, Ullmann N, Campbell GA, Sherburn RT, Mathie SA, et al. IL-33 promotes airway remodeling in pediatric patients with severe steroid-resistant asthma. Journal of Allergy and Clinical Immunology. 2013;132(3):676-685.e13.
13.
Durrani SR, Montville DJ, Pratt AS, Sahu S, DeVries MK, Rajamanickam V, et al. Innate immune responses to rhinovirus are reduced by the high-affinity IgE receptor in allergic asthmatic children. Journal of Allergy and Clinical Immunology. 2012;130(2):489–95.
14.
Daccorda C, Touillouxa B, Von Garniera C. Prise en charge de l’asthme et de la BPCO en situation de pandémie de COVID-19. Revue Médicale Suisse. 2020;16(692):933–8.
15.
Song J, Zeng M, Wang H, Qin C, Hou H, Sun Z, et al. Distinct effects of asthma and COPD comorbidity on disease expression and outcome in patients with COVID‐19. Allergy. 2021;76(2):483–96.
16.
Wang Y, Chen J, Chen W, Liu L, Dong M, Ji J, et al. Does Asthma Increase the Mortality of Patients with COVID-19?: A Systematic Review and Meta-Analysis. International Archives of Allergy and Immunology. 2021;182(1):76–82.
17.
Choi YJ, Park JY, Lee HS, Suh J, Song JY, Byun MK, et al. Effect of asthma and asthma medication on the prognosis of patients with COVID-19. European Respiratory Journal. 2021;57(3):2002226.
18.
Wakabayashi M, Pawankar R, Narazaki H, Ueda T, Itabashi T. Coronavirus disease 2019 and asthma, allergic rhinitis: molecular mechanisms and host–environmental interactions. Current Opinion in Allergy & Clinical Immunology. 2021;21(1):1–7.
19.
Castillo JR, Peters SP, Busse WW. Asthma Exacerbations: Pathogenesis, Prevention, and Treatment. The Journal of Allergy and Clinical Immunology: In Practice. 2017;5(4):918–27.
20.
Loftus PA, Wise SK. Epidemiology and economic burden of asthma. International Forum of Allergy & Rhinology. 2015;5(S1).
21.
O’Toole J, Mikulic L, Kaminsky DA. Epidemiology and Pulmonary Physiology of Severe Asthma. Immunology and Allergy Clinics of North America. 2016;36(3):425–38.
22.
Toskala E, Kennedy DW. Asthma risk factors. International Forum of Allergy & Rhinology. 2015;5(S1).
23.
Tan J, Bernstein JA. Occupational Asthma: An Overview. Current Allergy and Asthma Reports. 2014;14(5).
24.
Wu TD, Brigham EP, McCormack MC. Asthma in the Primary Care Setting. Medical Clinics of North America. 2019;103(3):435–52.
25.
Al-Karkhy MA, Nema M, Abdullah SF. Correlation of Prostaglandin D2 with disease severity of adult asthma. J Fac Med Bagdad. 2020;61:3–4.
26.
Jartti T, Gern JE. Role of viral infections in the development and exacerbation of asthma in children. Journal of Allergy and Clinical Immunology. 2017;140(4):895–906.
27.
Al-Zaidi MSh, Kadhim HS, Ahmed Shemran H. The possible association between Chlamydia pneumoniae infection and asthma. Journal of the Faculty of Medicine Baghdad. 52(3):318–9.
28.
Mims JW. Asthma: definitions and pathophysiology. International Forum of Allergy & Rhinology. 2015;5(S1).
29.
SARIOĞLU N. Asthma and COVID-19: What do we know? Tuberk Toraks. 2020;68(2):141–7.
30.
Galib BA. SARS-CoV-2(COVID-19. J Fac Med Bagdad. 2020;61:3–4.
31.
Taher TM, Sarray FT, Farhan Al-Badri SA, Ghazi HF. Comorbidity and Risk Factors for COVID-19 Confirmed Patients in Wasit Province, IRAQ. AL-Kindy College Medical Journal. 16(supplement):1–8.
32.
Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JPA, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Journal of Clinical Epidemiology. 2009;62(10):e1–34.
33.
Johnston SL. Asthma and COVID‐19: Is asthma a risk factor for severe outcomes? Allergy. 2020;75(7):1543–5.
34.
Chhiba KD, Patel GB, Vu THT, Chen MM, Guo A, Kudlaty E, et al. Prevalence and characterization of asthma in hospitalized and nonhospitalized patients with COVID-19. Journal of Allergy and Clinical Immunology. 2020;146(2):307-314.e4.
35.
Morais-Almeida M, Aguiar R, Martin B, Ansotegui IJ, Ebisawa M, Arruda LK, et al. COVID-19, asthma, and biological therapies: What we need to know. World Allergy Organization Journal. 2020;13(5):100126.
The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.
